As­traZeneca and Mer­ck hope new da­ta can PRO­pel their PARP in­hibitor in­to first-line prostate can­cer

Last year, Clo­vis’ PARP in­hibitor Rubra­ca beat As­traZeneca and Mer­ck’s block­buster Lyn­parza across the fin­ish line in prostate can­cer by a mat­ter of days. Now, the phar­ma part­ners are look­ing for a come­back in the first-line set­ting — and an in­ter­im look at Phase III da­ta could give them the boost they need.

When ad­min­is­tered in com­bi­na­tion with J&J’s Zyti­ga (a cur­rent stan­dard of care), Lyn­parza achieved a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in ra­di­ograph­ic pro­gres­sion-free sur­vival in a seg­ment of men with ad­vanced prostate can­cer, com­pared to Zyti­ga alone, As­traZeneca and Mer­ck an­nounced on Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER